Please login to the form below

Not currently logged in
Email:
Password:

Allergy specialist Circassia buys asthma firms

British-based company acquires Sweden’s Aerocrine and privately held Prosonix

Asthma inhaler  

Circassia Pharmaceuticals has bought two asthma-focused companies for $377m as it looks to expands its portfolio. 

The UK-based allergy specialist says it will purchase Sweden's Aerocrine and privately held Prosonix – two companies that both focus on asthma.

Circassia will pay £139m ($219m) for Aerocrine and up to £100m for Prosonix.

Circassia will use Aerocrine's established commercial operation to help with the launch of its new cat allergy treatment Cat-SPIRE.

Cat-SPIRE is due to report phase III clinical trial results in the first half of 2016.

Meanwhile, Prosonix provides a portfolio of products targeting asthma and other respiratory diseases that complement Circassia's existing pipeline.

Circassia's chief executive Steve Harris said the two deals would help his company become a self-sustaining business focused on allergy and asthma.

He told Reuters: “Aerocrine has products that they sell to allergy asthma specialists, the very customers we want to sell our allergy products to, so that's a really good strategic fit. 

“Prosonix has near-term products that help us create an allergy-asthma specialist pharmaceutical company.”

The asthma market is still highly competitive with a number of blockbuster products from AstraZeneca and GlaxoSmithKline taking billions of dollars in sales each year.

Many are now however facing the threat of patent expiries or pricing pressures, with GSK's respiratory business struggling to find growth in the past two years - although the FDA's approval of its new drug Breo should help shore up sales in the future. 

Next-gen therapies based on antibody design and generics are set to take over from previous blockbusters in the coming years, with Circassia hoping to gain a share of the new market. 

Article by
Ben Adams

18th May 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics